Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Philippines is the first market for lamivudine as anti-HBV agent

Dec. 14, 1998

FDA approves Rebetron combination therapy for previously untreated HCV patients

Dec. 11, 1998

The FDA approves lamivudine for the treatment of chronic HBV

Dec. 10, 1998

In vitro and clinical study results support development of nitazoxanide for H. pylori infection

Dec. 10, 1998

Eisai begins product launch of proton pump inhibitor in Germany

Dec. 8, 1998

Six-month treatment with ciprofloxacin improves response rate in ulcerative colitis

Dec. 4, 1998

Agents for ulcers synthesized and evaluated at Shiseido

Dec. 3, 1998

AxyS initiates phase I studies of APC-2059 for treatment of acute inflammatory bowel disease

Dec. 3, 1998

Lead SelCID compound poised to enter phase II clinical trials for Crohn's disease

Dec. 2, 1998

Health Canada approves lamivudine for treatment of chronic HBV

Dec. 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...